References
- Allen TM. Liposomal drug formulations: rationale for development and what we can expect for the future. Drugs. 1998; 56:747–56.982915010.2165/00003495-199856050-00001
- Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8:473–80.10.1038/nrc239418469827
- Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine. 2012; 7:1139–48.22412300
- Shek PN, Suntres ZE, Brooks JI. Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target. 1994; 2:431–42.770448810.3109/10611869408996819
- Parthasarathi G, Udupa N, Umadevi P, Pillai G. Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J Drug Target. 1994; 2:173–82.10.3109/106118694090159078069596
- Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Ghalandari R, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosome for pulmonary delivery. J Microencapsul. 2010; 27:618–27.10.3109/02652048.2010.50657920681747
- Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011; 1:208–19.10.1016/j.apsb.2011.09.002
- Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998; 172:33–70.10.1016/S0378-5173(98)00169-0
- Rangasamy M, Ayyasamy B, Raju S, Gummadevelly S, Shaik S. Formulation and in vitro evaluation of niosome encapsulated acyclovir. J Pharm Res. 2008; 1:163–6.
- Bhaskaran S, Lakshmi PK. Comparative evaluation of niosome formulations prepared by different techniques. Acta Pharma Sci. 2009; 51:27–32.
- Negi LM, Garg AK, Chauhan M. Ultradeformable vesicles: concept and execution. Pharma Times. 2009; 41:11–4.
- Sankar V, Ruckmani K, Jailani S, Ganesan KS, Sharavanan SP. Niosome drug delivery system: advances and medical applications – an overview. Pharmacologyonline. 2009; 2:926–32.
- Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci. 1995; 58:1–55.10.1016/0001-8686(95)00242-I
- Bouwstra JA, van Hal DA, Hofland HEJ, Junginger HE. Preparation and characterization of nonionic surfactant vesicles. Colloids Surf A: Physicochem Eng Aspects. 1997; 123–124:71–80.
- Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes—non-ionic surfactant vesicles. J Pharm Pharmacol. 1985; 37:863–68.286809210.1111/j.2042-7158.1985.tb04990.x
- Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: an updated review. Int J Pharma Investig. 2012; 2:2–11.10.4103/2230-973X.96920
- Thacharodi D, Rao KP. Development and in vitro evaluation of chitosan-based transdermal drug delivery system for the controlled delivery of propranolol hydrochloride. Biomaterials. 1995; 16:145–8.10.1016/0142-9612(95)98278-M
- Krishna R, Pandit JK. Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J Pharm Pharmacol. 1996; 48:367–70.10.1111/j.2042-7158.1996.tb05934.x8794984
- Bhat M, Shenoy DS, Udupa N, Srinivas CR. Optimization of delivery of betamethasone-dipropionate from skin preparation. Indian Drugs. 1995; 32:211–4.
- Diljyot K. Niosomes: a new approach to targeted drug delivery. Int J Pharm Phytopharm Res. 2012; 2:53–9.
- Malhotra M, Jain NK. Niosomes as drug carriers. Indian Drugs. 1994; 31:81–6.
- Giddi HS, Arunagirinathan MA, Bellare JR. Self-assembled surfactant nano-structures important in drug delivery: a review. Indian J Exp Biol. 2007; 45:133–59.17375554
- Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular systems: an overview. Indian J Pharm Sci. 2006; 68:141–53.10.4103/0250-474X.25707
- Bandyopadhyay P, Johnson M. Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release. Colloids Surf B Biointerfaces. 2007; 58:68–71.10.1016/j.colsurfb.2007.01.01417339104
- Shan W, Liu H, Shi J, Yang L, Hu N. Self-assembly of electroactive layer-by-layer films of heme proteins with anionic surfactant dihexadecyl phosphate. Biophys Chem. 2008; 134:101–9.1829475210.1016/j.bpc.2008.01.008
- Gandhi A, Sen SO, Paul A. Current trend in niosome as vesicular drug delivery system. Asian J Pharm Life Sci. 2012; 2:339–53.
- Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee SA, Behera M, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Tech Res. 2010; 1:374–80.10.4103/0110-5558.76435
- Sahin NO. Niosomes as nanocarrier systems. In: Mozafari MR, editor. Nanomaterials and nanosystems for biomedical applications. Dordrecht: Springer; 2007. p. 67–82.
- Keservani RK, Sharma AK, Ayaz Md, Kesharwani RK. Novel drug delivery system for the vesicular delivery of drug by the niosomes. Int J Res Controlled Release. 2011; 1:1–8.
- Khandare JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. The Eastern Pharmacist. 1994; 37:61–4.
- Jayaraman SC, Ramachandran C, Weiner N. Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study. J Pharm Sci. 1996; 85:1082–84.10.1021/js960040u
- Raja NRA, Pillai GK, Udupa N, Chandrashekhar G. Anti-inflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. Indian J Pharmacol. 1994; 26:46–8.
- Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. Cox B, editor. British Pharmaceutical Conference 1989, Science Proceedings 126th Meeting; 1989 September 11–14; Keele, United Kingdom. London: Royal Pharmacological Society of Great Britain. J Pharm Pharmacol. 1989; 41 Suppl:6P.
- Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta. 1985; 816:294–302.10.1016/0005-2736(85)90497-33839135
- Verma AK, Bindal JC. A vital role of niosomes on controlled and novel drug delivery. Indian J Novel Drug Deliver. 2011; 3:238–46.
- Aggarwal D, Garg A, Kaur IP. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J Pharm Pharmacol. 2004; 56:1509–17.10.1211/002235704489615563757
- Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm. 2002; 244:73–80.10.1016/S0378-5173(02)00301-012204566
- Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J Appl Pham Sci. 2012; 2:20–32.
- Udupa N. Niosomes as drug carriers. In: Jain NK, editor, Controlled and novel drug delivery. New Delhi: CBS Publishers and Distributors; 2002. p. 292–303.
- Muzzalupo R, Tavano L, Lai F, Picci N. Niosomes containing hydroxyl additives as percutaneous penetration enhancers: effect on the transdermal delivery of sulfadiazine sodium salt. Colloids Surf B Biointerfaces. 2014; 123:207–12.2526022010.1016/j.colsurfb.2014.09.017
- Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencapsul. 1987; 4:321–8.350451310.3109/02652048709021824
- Arunothayanun P, Bernard M-S, Craig DQM, Uchegbu IF, Florence AT. The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int J Pharm. 2000; 201:7–14.1086726010.1016/S0378-5173(00)00362-8
- Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F. Vesicles of non-ionic surfactants (niosomes) and drug delivery potential. Int J Pharm Sci Nanotech. 2008; 1:1–8.
- Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm. 1999; 185:23–5.1042536210.1016/S0378-5173(99)00122-2
- Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS PhamSciTech. 2007; 8:43. 10.1208/pt0804086.
- Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA. In vitro evaluation of proniosomes as a drug carrier for flurbiprofen. AAPS PhamSciTech. 2008; 9:782–90.10.1208/s12249-008-9114-0
- Reddy BS, Padman JSC, Santosh V. Niosomes as nanocarrier systems: a review. Int J Pharm Sci Res. 2012; 3:1560–68.
- Zasadzinski JA, Wong B, Forbes N, Gary B, Wu G. Novel methods of enhanced retention in and rapid, targeted release from liposomes. Curr Opin Colloid Interface Sci. 2011; 16:203–14.10.1016/j.cocis.2010.12.00421603081
- Yoo J-W, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev. 2011; 63:1247–56.10.1016/j.addr.2011.05.00421605607
- Chakraborty S, Shukla D, Mishra B, Singh S. Lipid – An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009; 73:1–15.10.1016/j.ejpb.2009.06.00119505572
- Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biol Pharm Bull. 2011; 34:945–53.2171999610.1248/bpb.34.945
- Mujoriya RZ, Dhamande K, Bodla RB. Niosomal drug delivery system – a review. Int J Appl Pharm. 2011; 3:7–10.
- Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother. 1999; 44:791–4.10.1093/jac/44.6.79110590280
- Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr. 1992; 5:60–4.1346633
- Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao RB, Rambhau D. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci. 2002; 251:360–65.1629074110.1006/jcis.2002.8399
- Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PhamSciTech. 2010; 11:1119–27.10.1208/s12249-010-9480-2
- Cummings J, Stuart JFB, Calman KC. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1984; 311:125–33.10.1016/S0378-4347(00)84698-8
- Udupa N, Chandraprakash KS, Umadevi P, Pillai GK. Formulation and evaluation of methotrexate niosomes. Drug Dev Indust Pharm. 1993; 19:1331–42.10.3109/03639049309074404
- Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm. 2008; 353:233–42.1819150910.1016/j.ijpharm.2007.11.037
- Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids. 1995; 30:1139–43.10.1007/BF025366158614304
- Fu J-Y, Tan DMY, Er HM, Chen YS, Nesaretnam K. Tumor-targeted niosome as novel carrier for intravenous administration of tocotrienol. Sriamornsak P, Limmatvapirat S, Piriyaprasarth S, editors. Asian Federation for Pharmaceutical Sciences (AFPS) 2015 Conference; 2015 Nov 25–27. Bangkok, Thailand. Asian J Pharm Sci. 2016; 11:79–80.
- Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015; 35:645–51.25667441
- Xu YQ, Chen WR, Tsosie JK, Xie X, Li P, Wan J, et al. Niosome encapsulation of curcumin: characterization and cytotoxic effect on ovarian cancer cells. J Nanomater. 2016; 2016:6365295. 9p. 10.1155/2016/6365295.
- Sharma V, Anandhakumar S, Sasidharan M. Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. Mater Sci Eng C Mater Biol Appl. 2015; 56:393–400.10.1016/j.msec.2015.06.04926249606
- Antimalaria Coordinating Research Group. Antimalaria studies on qinghaosu. Chin Med J. 1979; 92:811–6.
- Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012; 2012:247597. 10.1155/2012/247597.22174561
- Li Q, Weina PJ, Milhous WK. Pharmacokinetic and pharmacodynamic profiles of rapid-acting artemisinins in the antimalarial therapy. Curr Drug Ther. 2007; 2:210–23.10.2174/157488507781695649
- Dwivedi A, Mazumder A, du Plessis L, du Preez JL, Haynes RK, du Plessis J. In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomedicine. 2015; 11:2041–50.10.1016/j.nano.2015.07.01026282380
- Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971; 25:270–75.10.1038/bjc.1971.335115829
- Shaker DS, Shaker MA, Hanafy MS. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. Int J Pharm. 2015; 493:285–94.2620074810.1016/j.ijpharm.2015.07.041
- Tila D, Yazdani-Arazi SN, Ghanbarzadeh S, Arami S, Pourmoazzen Z. pH-sensitive, polymer modified, plasma stable niosomes: promising carriers for anti-cancer drugs. EXCLI J. 2015; 14:21–32.26417350
- Li M, Tang Z, Zhang Y, Lv S, Li Q, Chen X. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomater. 2015; 18:132–43.10.1016/j.actbio.2015.02.02225735801
- Kanaani L, Javadi I, Ebrahimifar M, Ebrahimi shahmabadi H, Akbarzadeh Khiyavi A, Mehrdiba T. Effects of cisplatin-loaded niosomal nanoparticles on BT-20 human breast carcinoma cells. Asian Pac J Cancer Prev. 2017; 18:365–8.28345332
- Shilpa S, Srinivasan BP, Chauhan M. Niosomes as vesicular carriers for delivery of proteins and biologicals. Int J Drug Delivery. 2011; 3:14–24.10.5138/ijdd.2010.0975.0215.03050
- Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M. Non-phospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm. 2005; 59:57–62.10.1016/j.ejpb.2004.06.01015567302
- Singh G, Dwivedi H, Saraf SK, Saraf SA. Niosomal delivery of isoniazid – development and characterization. Trop J Pharm Res. 2011; 10:203–10.
- Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics. Indian J Pharm Sci. 2006; 68:575–8.10.4103/0250-474X.29622
- Kaur K, Gupta A, Narang RK, Murthy RSR. Novel drug delivery system: desired feat for tuberculosis. J Adv Pharm Tech Res. 2010; 1:145–63.
- Mullaicharam AR, Murthy RSR. Lung accumulation of niosome-entrapped gentamicin sulfate follows intravenous and intratracheal administration in rats. J Drug Deliv Sci Tech. 2006; 16:109–13.10.1016/S1773-2247(06)50016-4
- Muzzalupo R. Niosomes and proniosomes for enhanced skin delivery. In: Dragicevic N, Maibach H, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement. Heidelberg: Springer; 2016. p. 147–60.
- Fathalla D, Abdel-Mageed A, Abdel-Hamid F, Ahmed M. In-vitro and in-vivo evaluation of niosomal gel containing aceclofenac for sustained drug delivery. Int J Pharm Sci Res. 2014; 1:105. 10.15344/2394-1502/2014/105.
- Kumbhar D, Wavikar P, Vavia P. Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity. AAPS PhamSciTech. 2013; 14:1072–82.10.1208/s12249-013-9986-5
- Kamboj S, Saini V, Bala S, Sharma G. Formulation and characterization of drug loaded niosomal gel for anti-inflammatory activity. Int J Med Health Biomed Bioeng Pharm Eng. 2013; 7:877–81.
- Shinde UA, Kanojiya SS. Serratiopeptidase niosomal gel with potential in topical delivery. J Pharm (Cario). 2014; 2014:9. 10.1155/2014/382959.
- Fukai T, Satoh K, Nomura T, Sakagami H. Preliminary evaluation of antinephritis and radical scavenging activities of glabridin from Glycyrrhiza glabra. Fitoterapia. 2003; 74:624–9.10.1016/S0367-326X(03)00164-314630165
- Morteza-Semnani K, Saeedi M, Shahnavaz B. Comparison of antioxidant activity of extract from roots of licorice (Glycyrrhiza glabra L.) to commercial antioxidants in 2% hydroquinone cream. J Cosmet Sci. 2003; 54:551–8.14730371
- Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release. 2005; 106:99–110.1593550510.1016/j.jconrel.2005.04.007
- Matsui S, Matsumoto H, Sonoda Y, Ando K, Aizu-Yokota E, Sato T, et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 2004; 4:1633–44.10.1016/j.intimp.2004.07.023
- Marianecci C, Rinaldi F, Mastriota M, Pieretti S, Trapasso E, Paolino D, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012; 164:17–25.10.1016/j.jconrel.2012.09.01823041542
- Priprem A, Janpim K, Nualkaew S, Mahakunakorn P. Topical niosome gel of Zingiber cassumunar Roxb. extract for anti-inflammatory activity enhanced skin permeation and stability of compound D. AAPS PhamSciTech. 2016; 17:631–9.10.1208/s12249-015-0376-z
- Leelarungrayub J, Manorsoi J, Manorsoi A. Anti-inflammatory activity of niosomes entrapped with Plai oil (Zingiber cassumunar Roxb.) by therapeutic ultrasound in a rat model. Int J Nanomedicine. 2017; 12:2469–76.10.2147/IJN.S129131
- Jang M, Cai L, Udeani GO. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275:218–20.898501610.1126/science.275.5297.218
- Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomás-Barberán FA, García-Conesa MT, Espín JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Cur Pharma Des. 2013; 19:6064–93.10.2174/13816128113199990407
- Davidov-Pardo G, McClements DJ. Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci Technol. 2014; 38:88–103.10.1016/j.tifs.2014.05.003
- Negi P, Aggarwal M, Sharma G, Rathore C, Sharma G, Singh B, et al. Niosome-based hydrogel of resveratrol for topical applications: an effective therapy for pain related disorder(s). Biomed Pharmacother. 2017; 88:480–87.2812667310.1016/j.biopha.2017.01.083
- van Sorge AA, Wijnen PH, van Delft JL, Coré-Bodelier VM, van Haeringen NJ. Flurbiprofen, S(+), eyedrops: formulation, enantiomeric assay, shelf life and pharmacology. Pharm World Sci. 1999; 21:91–5.1038023710.1023/A:1008609513880
- Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Delivery Rev. 1995; 16:39–43.10.1016/0169-409X(95)00012-V
- Zhang W, Prausnitz MR, Edwards A. Model of transient drug diffusion across cornea. J Control Release. 2004; 99:241–58.1538063410.1016/j.jconrel.2004.07.001
- El-Sayed MM, Hussein AK, Sarhan HA, Mansour HF. Flurbiprofen-loaded niosomes-in-gel system improves the ocular bioavailability of flurbiprofen in the aqueous humor. Drug Dev Ind Pharm. 2017; 43:902–10.2797731110.1080/03639045.2016.1272120
- Wagh VD, Deshmukh OJ. Itraconazole niosomes drug delivery system and its antimycotic activity against Candida albicans. ISRN Pharm. 2012; 2012:653465.23378932
- Alam M, Zubair S, Farazuddin M, Ahmad E, Khan A, Zia Q, et al. Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. Nanomedicine. 2013; 9:247–56.10.1016/j.nano.2012.07.00422858760
- Fetih G. Fluconazole-loaded niosomal gels as a topical ocular drug delivery system for corneal fungal infections. J Drug Deliv Sci Technol. 2016; 35:8–15.10.1016/j.jddst.2016.06.002
- Gupta A, Kar HK. Antidermatophytic activity of miconazole nanoformulation against Trichophyton rubrum. Asian Pac J Trop Dis. 2015; 5:707–10.10.1016/S2222-1808(15)60917-3
- de Arauz LJ, Jozala AF, Mazzola PG, Penna TCV. Nisin biotechnological production and application: a review. Trends Food Sci Technol. 2009; 20:146–54.10.1016/j.tifs.2009.01.056
- Boziaris IS, Adams MR. Effect of chelators and nisin produced in situ on inhibition and inactivation of Gram negatives. Int J Food Microbiol. 1999; 53:105–13.10.1016/S0168-1605(99)00139-710634702
- Kopermsub P, Mayen V, Warin C. Potential use of niosomes for encapsulation of nisin and EDTA and their antibacterial activity enhancement. Food Res Int. 2011; 44:605–12.10.1016/j.foodres.2010.12.011
- Kellner R, Jung G, Hörner T, Zähner H, Schnell N, Entian KD, et al. Gallidermin: a new lanthionine-containing polypeptide antibiotic. Eur J Biochem. 1988; 177:53–9.10.1111/j.1432-1033.1988.tb14344.x3181159
- Manosroi A, Khanrin P, Lohcharoenkal W, Werner RG, Götz F, Manosroi W, et al. Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes. Int J Pharm. 2010; 392:304–10.10.1016/j.ijpharm.2010.03.06420381599
- Burdock G. Review of the biological properties and toxicity of bee propolis (propolis). Food Chem Toxicol. 1998; 36:347–63.10.1016/S0278-6915(97)00145-29651052
- Patel J, Ketkar S, Patil S, Fearnley J, Mahadik KR, Paradkar AR. Potentiating antimicrobial efficacy of propolis through niosomal-based system for administration. Integr Med Res. 2015; 4:94–101.10.1016/j.imr.2014.10.00428664114
- Zubairu Y, Negi LM, Iqbal Z, Talegaonkar S. Design and development of novel bioadhesive niosomal formulation for the transcorneal delivery of anti-infective agent: In-vitro and ex-vivo investigations. Asian J Pharm Sci. 2015; 10:322–30.10.1016/j.ajps.2015.02.001
- Sohrabi S, Haeri A, Mahboubi A, Mortazavi A, Dadashzadeh S. Chitosan gel-embedded moxifloxacin niosomes: an efficient antimicrobial hybrid system for burn infection. Int J Biol Macromol. 2016; 85:625–33.10.1016/j.ijbiomac.2016.01.01326794314
- Wagner VE, Iglewski BH. Pseudomonas aeruginosa biofilms in CF infection. Clin Rev Allergy Immunol. 2008; 35:124–34.10.1007/s12016-008-8079-918509765
- Mahdiun F, Mansouri S, Khazaeli P, Mirzaei R. The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa. Microb Pathog. 2017; 107:129–35.10.1016/j.micpath.2017.03.01428323149
- Borowska K, Wolowiec S, Rubaj A, Glowniak K, Sieniawska E, Radej S. Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene-In vivo study. Int J Pharm. 2012; 426:280–83.10.1016/j.ijpharm.2012.01.041
- Kassem AA, Abd El-Alim SH, Asfour MH. Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles: formulation development, in vitro and in vivo evaluation of skin deposition. Int J Pharm. 2017; 517:256–68.2795619410.1016/j.ijpharm.2016.12.018
- Jacob S, Nair AB, Al-Dhubiab BE. Preparation and evaluation of niosome gel containing acyclovir for enhanced dermal deposition. J Liposome Res. 2017; 27:283–92.10.1080/08982104.2016.122489727558522
- Cortesi R, Esposito E. Acyclovir delivery systems. Expert Opin Drug Deliv. 2008; 5:1217–30.10.1517/1742524080245034018976132
- Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017; 254:55–64.2834780710.1016/j.jconrel.2017.03.386
- Opanasopit P, Leksantikul L, Niyomtham N, Rojanarata T, Ngawhirunpat T, Yingyongnarongkul BE. Cationic niosomes an effective gene carrier composed of novel spermine-derivative cationic lipids: effect of central core structures. Pharm Dev Technol. 2017; 22:350–59.10.3109/10837450.2015.112592526708923
- Hashemi Dehaghi M, Haeri A, Keshvari H, Abbasian Z, Dadashzadeh S. Dorzolamide loaded niosomal vesicles: comparison of passive and remote loading methods. Iran J Pharm Res. 2017; 16:413–22.28979296
- Hsu CY, Chen CH, Aljuffali IA, Dai YS, Fang JY. Nanovesicle delivery to the liver via retinol binding protein and platelet-derived growth factor receptors: how targeting ligands affect biodistribution. Nanomedicine (Lond). 2017; 12:317–31.10.2217/nnm-2016-031928078954
- Moghassemi S, Hadjizadeh A, Hakamivala A, Omidfar K. Growth factor-loaded nano-niosomal gel formulation and characterization. AAPS PharmSciTech. 2017; 18:34–41.10.1208/s12249-016-0579-y27502406
- Moghassemi S, Hadjizadeh A, Omidfar K. Formulation and characterization of bovine serum albumin-loaded niosome. AAPS PharmSciTech. 2017; 18:27–33.10.1208/s12249-016-0487-126817764